NAIROBI, Kenya – Amid an ongoing, deadly outbreak of the rare but lethal Bundibugyo strain of Ebola in the eastern Democratic Republic of Congo, Africa’s top public health agency has laid out a clear timeline to deliver the first targeted vaccine and treatment for the virus by the end of 2026. Jean Kaseya, director of the Africa Centres for Disease Control and Prevention (Africa CDC), confirmed the aggressive development timeline during a Thursday online press briefing with reporters, noting that multiple promising vaccine candidates are already in the pipeline for evaluation. The Bundibugyo Ebola strain, which triggered the current large-scale outbreak in the DRC starting this spring, currently has no globally approved preventative vaccines or specific antiviral treatments, leaving frontline healthcare workers with limited tools to slow transmission or reduce mortality. Kaseya emphasized that both political leadership and technical teams are fully committed to accelerating development, stating that investment is already flowing into both strategic and technical stages of the project to ensure the goal is met. “What we can tell you for sure, by the end of this year, 2026, Africa CDC will make sure that we have a vaccine and medicine against Bundibugyo,” Kaseya told reporters. “Our leaders are ready to invest. We are investing at technical level, at a strategic level, to make sure that (the vaccine) will happen.” The development update comes as Kaseya also confirmed he received recent correspondence from Russia’s Ministry of Health claiming that Russian researchers have already completed development of a vaccine targeting the Bundibugyo strain. A senior Africa CDC team member later clarified that the Russian vaccine candidate is currently designed to target the more common Zaire strain of Ebola, and upcoming technical discussions with Moscow’s Gamaleya National Research Centre will explore the underlying science supporting the candidate’s claimed cross-protection against the Bundibugyo variant. As of the latest briefing, Kaseya reported at least 1,077 suspected cases of Ebola tied to the outbreak, which was formally declared on May 15. That total includes 246 recorded deaths from the virus. Kaseya’s figures are slightly higher than the most recent official count released by the World Health Organization, which has reported 10 confirmed Ebola deaths and 223 suspected fatalities linked to the ongoing outbreak. Public health experts have warned that unregulated cross-border movement in the Great Lakes region and weak healthcare infrastructure in eastern DRC increase the risk of the outbreak spreading beyond national borders, making rapid development of targeted medical countermeasures a top regional priority.
分类: health
-

Guyana offers Caribbean training, long-distance robotic telesurgery
In a landmark breakthrough that redefines the boundaries of modern medical innovation, the South American nation of Guyana has successfully completed the world’s longest-distance robotic-assisted telesurgery, marking a new era in accessible, high-precision healthcare across the Caribbean region. The unprecedented procedure, performed on May 26, 2026, saw internationally renowned cardiac surgeon Dr. Sudhir Srivastava, founder of India-based SS Innovations, conduct a Coronary Artery Bypass Graft (CABG) on a patient located 20,000 kilometers away in India, operating from a control room at Georgetown Public Hospital (GPHC) in Guyana.
President Irfaan Ali announced the historic achievement at an official press briefing Tuesday night, alongside Health Minister Dr. Frank Anthony and a multi-national team of medical specialists. He emphasized that Guyana’s new technological leap positions the country to serve as a regional hub for robotic surgery, extending access to this cutting-edge care to all member states of the Caribbean Community (CARICOM).
“What patients can access in the most advanced medical facilities in India will be available right here in Guyana for the entire region in the coming weeks,” President Ali stated. “Our plan builds a central robotics, surgery and care hub based in Guyana, with outposts across the Caribbean, and we will provide full training for medical teams from every CARICOM nation.” To support this initiative, Guyana has purchased a complete robotic surgery training module and finalized an agreement with SS Mantra, the Indian developer of the surgical system used in the procedure, to establish an accredited international training center on its soil. Previously, all of Guyana’s surgical teams traveled to India to complete certification on the system.
Health Minister Dr. Frank Anthony confirmed the training program will receive formal accreditation and will be integrated into post-graduate fellowship training offered through the University of Guyana and the Ministry of Health. The milestone telesurgery procedure beat the previous world record for the longest-distance robotic surgery, also set by SS Mantra for a procedure between Australia and India. Multiple layers of internet redundancy were built into the operation, with an on-site Indian surgical team on standby to take over if connectivity issues arose, and the procedure was completed without complications.
Alongside the historic telesurgery milestone, GPHC also announced a second first for the English-speaking Caribbean: the first fully local robotic surgery, a successful inguinal hernia repair performed by Guyanese surgeon Dr. Hemraj Ramcharran, with support from Dr. Bibi Hussain and Dr. Jagnanand Ramnarine. Ramcharran is now the first Caribbean surgeon to complete a robotic procedure within the region.
Medical experts outlined the transformative benefits of the latest-generation SSI Mantra robotic system, noting it delivers high-resolution 3D magnified views of surgical sites and allows for precision control of tissue manipulation within fractions of a millimeter — a level of accuracy impossible to achieve with traditional open surgery. Unlike conventional open-heart surgery that requires splitting the sternum (breastbone), robotic-assisted procedures use small incisions between ribs to access the surgical site, drastically reducing patient recovery time, blood loss, post-operative infection risk, and complications such as deep vein thrombosis.
Cost is another major advantage: traditional open-heart surgery typically costs between $6,000 and $12,000 U.S. dollars, including a minimum seven-day post-operative hospital stay, while robotic-assisted surgery cuts that cost by 50%. Critically, GPHC announced it will offer all robotic-assisted procedures to patients completely free of charge.
To advance the expansion of robotic surgery in Guyana and the region, President Ali has established a new Robotics Advisory Committee, co-chaired by prominent Guyanese cardiologist Dr. Mahendra Carpen, with members including Dr. Anthony, Dr. Riyad Gafoor, Satindra Prasad, and Steve Carryl. Officials are already working to address remaining gaps in local expertise, including training for a perfusionist — a specialized clinician who operates the heart-lung machine used during cardiac surgery — with SS Innovations assisting with placement for international training.
Barbados Prime Minister Mia Mottley, who delivered remarks at the briefing, welcomed Guyana’s regional offer, noting the new hub will help reduce the growing backlog of delayed surgeries across CARICOM member states. GPHC officials called the dual achievements a groundbreaking milestone in global healthcare, positioning Guyana as a leader in medical innovation and expanding access to life-saving care for underserved populations across the Caribbean.
-

HEBERSaVax: The story of a Cuban product, unique in the world, with great potential in the fight against cancer
On the afternoon of May 27, 2026, Cuban President Miguel Díaz-Canel Bermúdez, who also serves as First Secretary of the Central Committee of the Communist Party of Cuba, chaired a regular meeting of health sector experts and scientists at Havana’s Palace of the Revolution. The gathering’s most anticipated highlight was an update on HEBERSaVax, a groundbreaking Cuban-developed therapeutic vaccine candidate for treating multiple types of malignant tumors, a development that has already sparked early optimism for global cancer care.
During the session, Díaz-Canel extended formal congratulations to HEBERSaVax lead scientist Yanelys Morera Díaz, a full member of the Cuban Academy of Sciences, and her entire research team. Following the conclusion of the meeting, Morera spoke to state press about the vaccine’s mechanism and developmental progress, outlining how the innovative candidate works to stop cancer progression.
Morera explained that HEBERSaVax functions as a form of active immunotherapy, targeting two critical aspects of tumor growth. First, it prompts the body to produce specific antibodies that block the blood supply tumors need to access nutrients and oxygen for expansion. Second, it reactivates the patient’s own immune system to recognize and attack cancer cells, creating a multi-functional approach to treatment.
After completing all preclinical testing, including early trials in laboratory animal models, the candidate has advanced to Phase II clinical trials focused on specific tumor types. Morera emphasized that early safety data shows the therapy has a strong tolerability profile, with only mild, manageable adverse effects. This low toxicity profile allows HEBERSaVax to be combined with conventional cancer treatments without increasing harmful side effects, opening the door for broad clinical applications. While the candidate remains in active research, Morera noted that many trial participants have already reported meaningful improvements to their quality of life, with some patients with advanced-stage cancer achieving complete responses to treatment. Moving forward, the research team must continue compiling clinical evidence to meet Cuba’s rigorous national regulatory standards before advancing to later trial phases. Morera expressed confidence that the candidate will successfully complete all required testing and eventually become a core tool in global cancer treatment, with long-term plans to integrate the therapy into primary care settings.
Other members of the research team echoed Morera’s cautious optimism. Julio César Hernández Perera, an internal medicine specialist, full member of the Cuban Academy of Sciences and clinical researcher on the project, described HEBERSaVax as a one-of-a-kind achievement of Cuba’s robust biotechnology sector, built on decades of targeted research. He noted that the candidate could eventually be used to treat a wide range of solid tumors, which often rely on the specific protein targeted by the vaccine to grow and spread. Its low toxicity makes it a viable option even for patients living with multiple chronic conditions, a major advantage over many conventional aggressive treatments. Like Morera, Hernández Perera called for continued research investment, but stressed that the candidate already opens new, previously unreachable frontiers in cancer care.
Young clinical researcher Adriana Felinciano Pozo, another internal medicine specialist on the team, added that HEBERSaVax’s simple subcutaneous administration makes it easy to deploy in a wide range of care settings. Early trial results across multiple hard-to-treat solid tumor types — including colorectal cancer, hepatocellular carcinoma, ovarian cancer, and kidney cancer, all in advanced patient populations — have delivered consistent positive responses. Felinciano Pozo emphasized that cancer remains one of the leading global causes of death and long-term disability, making accessible, low-toxicity new therapies a critical global public health need.
The report frames HEBERSaVax’s development as a testament to Cuba’s enduring commitment to protecting the fundamental human right to health and life, even amid long-standing external economic pressure that has strained the country’s resources. The work of the HEBERSaVax research team exemplifies how Cuban biotechnology continues to advance life-saving innovation despite significant challenges.
-

UN says Ebola response in DR Congo faces challenges amid rising suspected cases
The Democratic Republic of the Congo (DRC) is grappling with an accelerating Ebola outbreak that has sent suspected case and death counts climbing, prompting global health bodies and humanitarian networks to ramp up emergency interventions on the ground. Latest figures compiled by the World Health Organization (WHO) put the total number of suspected infections above 900, with roughly 220 people already suspected to have died from the virus, underscoring the rapid spread of the disease across affected regions.
As global response efforts intensify, WHO Director-General Tedros Adhanom Ghebreyesus has announced plans to travel to the DRC to personally oversee and coordinate the outbreak response, according to a spokesperson for the United Nations Secretary-General. In a recent public update shared via social media, Tedros outlined that the WHO and 55 partner humanitarian organizations are already embedded in impacted communities, delivering not just Ebola-specific care but also critical basic health services, including life-saving treatment for acute malnutrition that disproportionately endangers local children and vulnerable groups.
WHO technical and operational teams are working hand-in-hand with DRC national health authorities across nearly every pillar of outbreak control. Their work spans critical activities ranging from tracking close contacts of confirmed cases to managing active infections, upgrading infection prevention protocols in healthcare facilities, strengthening local laboratory capacity to process test results quickly, running dedicated Ebola treatment centers, engaging local community leaders to build trust, and communicating clear public health guidance to at-risk populations.
Despite this coordinated push, major barriers continue to hinder the response. The UN has issued a stark warning that persistent insecurity and active violence in some of the most heavily affected hard-to-reach areas have thrown major logistical and safety challenges in the path of response teams, severely limiting their ability to reach isolated, vulnerable communities that need care the most.
Working in close partnership with the DRC national government, the UN and its humanitarian allies are moving forward with plans to expand emergency operations, while also working to address the broader long-standing humanitarian and healthcare gaps that leave communities more vulnerable to Ebola spread. The UN spokesperson emphasized that two critical needs remain unmet: urgent, sustained funding to scale up operations, and guaranteed safe access for response teams. These resources are essential not only to protect frontline responders from infection, but to ensure they can deliver comprehensive care and full life-saving aid packages to every community impacted by the outbreak.
-

CARPHA expands Caribbean early warning systems for vector-borne diseases
The Caribbean Public Health Agency (CARPHA) is pushing forward landmark efforts to boost the region’s capacity to detect and respond to vector-borne diseases, rolling out expanded regional surveillance networks and cutting-edge monitoring technologies through a collaborative multi-country workshop held recently in Guyana.
Held from April 27 to 28, 2026 at the Pegasus Hotel Exhibition Centre in Georgetown, the Regional Multisectoral Workshop, officially titled “Advancing Regional Vector-Borne Disease Surveillance through Technology and Harmonisation,” marks the latest milestone in a multi-phase regional public health initiative funded entirely through CARPHA’s Pandemic Fund Project. The convening gathered 28 key stakeholders, including senior epidemiology and vector control officials from 12 CARPHA member states, leadership from the Caribbean Vector-Borne Disease Network Steering Committee, and CARPHA’s in-house technical public health experts.
This Georgetown gathering builds on two prior successful regional workshops held in Barbados (August 2025) and Trinidad and Tobago (December 2025), where participants focused on foundational topics including Integrated Vector Management, insecticide resistance testing, and the application of Geographic Information Systems (GIS) to Caribbean pandemic preparedness. Unlike earlier sessions that laid operational groundwork, the 2026 workshop centered on streamlining cross-border collaboration: participants worked to standardize regional disease datasets, validate unified early warning indicators, and integrate modern digital tools to enable faster, evidence-based decision-making across three core areas: epidemiological tracking, climate monitoring, and vector population surveillance.
Lisa Indar, a senior CARPHA official, emphasized the ongoing urgency of the effort in her remarks, noting that vector-borne illnesses remain a persistent, major strain on Caribbean health systems and local communities. “As vector-borne diseases continue to pose a significant threat to Caribbean health systems and communities, CARPHA is working with Member States to strengthen the systems needed to detect risks earlier and respond more effectively,” Indar explained. “Through CARPHA’s Pandemic Fund Project, we are advancing integrated early warning systems, building technical capacity, and supporting the use of data and new technologies to guide timely public health action across the Region.”
Horace Cox, CARPHA’s Director of Surveillance, Disease Prevention and Control, echoed this focus, noting that robust, standardized surveillance forms the backbone of any effective public health preparedness framework. “Effective surveillance is at the centre of public health preparedness. By strengthening the way countries collect, analyse, and share vector-borne disease data, we are improving the Caribbean’s ability to detect threats earlier and coordinate timely responses across the region,” Cox said.
Roshan Parasram, another leading public health figure involved in the initiative, highlighted why modern, structured vector control systems are non-negotiable for Caribbean public health safety. “We are here because the Caribbean deserves a public health system that can see threats coming and act before they become crises,” Parasram stated. “We have built our approach on three pillars: Integrated Vector Management, Insecticide Resistance Testing, and Geographic Information Systems. These are not buzzwords. They are the operational backbone of a modern vector control system.”
Brian Armour, who leads work on regional early warning infrastructure for CARPHA, further outlined the value of integrating vector surveillance into broader regional public health systems. “Our Regional Integrated Early Warning and Response System (RIEWSS) is about connecting data, systems, and people so that public health threats can be identified and acted upon more quickly,” Armour explained. “The integration of vector-borne disease surveillance into this broader early warning framework is an important step toward a more coordinated, data-driven approach to pandemic preparedness and response in the Caribbean.”
Over the course of the two-day workshop, participants conducted in-depth reviews of proposed regional early warning indicators and evaluated methodologies to unify data collection and reporting across epidemiology, entomology, climate science, and geographic information systems. Technical breakout sessions explored the practical application of a range of innovative tools, including DHIS2 digital workflows, insecticide resistance analytics platforms, satellite remote sensing technology, artificial intelligence-powered risk mapping, and social listening tools designed to improve situational awareness and cut response times for public health agencies.
Among the tools highlighted, DHIS2 — an open-source digital health information management platform — was singled out as a core enabling technology for the region’s new surveillance framework. The platform is designed to streamline the collection, analysis, and visualisation of public health data, enabling faster detection and response to emerging disease outbreaks.
In addition to digital technology, participants also discussed new vector control innovations, including spatial repellents and emanator products engineered for use in the Caribbean’s densely populated urban centers. The workshop also included working sessions to review plans for formalizing the governance structure of the Caribbean Vector-Borne Disease Network Steering Committee and aligning stakeholders on the body’s upcoming work agenda.
A key outcome of the convening was the opportunity for individual member states to assess which technologies and interventions best fit their unique national epidemiological contexts, while also mapping out the infrastructure, cross-border partnerships, and workforce training required to roll out new systems locally. CARPHA officials noted that the discussions and agreements reached at the workshop are expected to improve the consistency and timeliness of regional disease data reporting, strengthen cross-border coordination, and enable more targeted, effective vector control measures across the entire Caribbean region.
-

The Bahamas issues travel ban amid Ebola outbreak
The Caribbean nation of The Bahamas has become the latest country to implement travel restrictions targeting three African nations grappling with a regional Ebola outbreak, barring all incoming travelers from the Democratic Republic of Congo, Uganda, and South Sudan.
The temporary entry prohibition was announced publicly in an official press statement released by the country’s Davis administration this week, confirming that the policy was drafted in direct response to formal guidance issued by The Bahamas’ Ministry of Health and Wellness. The restrictive measure went into effect immediately upon announcement, with an initial 30-day validity period that will be reassessed by public health officials at the end of that window to determine whether extension or adjustment is needed.
In the official statement, the administration emphasized that the ban was enacted as a proactive precautionary public health step, rooted in the government’s core obligation to safeguard the health of domestic residents, visiting tourists, and the broader national community. “The Ministry of Health and Wellness will continue to monitor developments of the African outbreak closely and will provide updated guidance to the government as shifting circumstances demand,” the statement noted. It added that the country’s Department of Immigration, working in tandem with national border control agencies and public health institutions, will roll out mandatory entry screening protocols at all of The Bahamas’ ports of entry to enforce the ban.
Alongside the new entry ban, The Bahamas’ Ministry of Foreign Affairs has issued a formal travel advisory urging all Bahamian citizens to cancel all non-essential travel to the three restricted countries. The advisory also urges Bahamians to exercise heightened caution when planning travel to eight additional African nations: Kenya, Tanzania, Rwanda, Burundi, Angola, the Central African Republic, Ethiopia, and Zambia, all of which neighbor current outbreak zones.
The government’s policy update comes as multiple regions across Central Africa are fighting a growing Ebola outbreak that has already resulted in hundreds of confirmed infections and deaths. The announcement also follows closely on the heels of a recent public health scare at one of the country’s major international airports, which unfolded after two foreign travelers arrived in The Bahamas on a British Airways flight originating from London’s Heathrow Airport this past Friday.
The two passengers, one a citizen of the United Kingdom and the other a French national, had completed a three-week stay in the Democratic Republic of Congo before traveling onward to Ethiopia, and eventually to New Providence, The Bahamas’ most populous island. During routine entry health screening at Lynden Pindling International Airport, both men were found to have low-grade fevers, prompting health officials to immediately isolate them on-site before transferring them to the Princess Margaret Hospital for further monitoring and testing.
As of the latest official update from Health Minister Dr. Michael Darville, the two individuals remain in isolation and are reported to be in stable, good condition. No additional Ebola-specific symptoms have been detected in either patient to date. “All required diagnostic testing is currently underway, and we will issue a public statement to media outlets as soon as the process is complete,” Darville said.
Ebola is a rare, frequently severe and often fatal infectious disease caused by a group of viruses in the Orthoebolavirus genus. Early symptoms of infection typically include fever, intense headache, muscle and joint pain, fatigue, sore throat, and general weakness. In severe cases that progress, the disease advances to cause vomiting, diarrhea, and severe abdominal pain. To date, the Bahamas has not recorded any confirmed domestically detected cases of Ebola.




